Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 8;8(4):395–407. doi: 10.1002/cjp2.265

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Impact of biopsy site and tumor content on the ability of an automated RNA‐Seq based classifier (SCOPE) to provide the correct putative diagnosis in the POG cohort. (A) The outcome from SCOPE is shown separated by the site of biopsy of the tumor. M and P indicate the number of metastatic and primary/relapse samples, respectively. (B) The distribution of cases across all biopsy sites is shown as a function of tumor content. (C) The majority of samples arose from three biopsy sites, lymph node, lung, and liver, indicated in each of the panels. Liver biopsies with low tumor content led to the highest number of conflicting (incorrect) assessments from SCOPE. A statistically significant association was found between SCOPE misprediction in liver biopsies and tumor content (p < 0.001, Wilcox test, not shown in figure).